Journal article
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study
Abstract
BACKGROUND: Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH) is characterized by swelling of subcutaneous and/or submucosal tissues.
OBJECTIVE: To evaluate efficacy/safety of fixed-dose subcutaneous plasma-derived C1-INH (pdC1-INH) liquid for HAE attack prevention (NCT02584959).
Authors
Lumry WR; Martinez-Saguer I; Yang WH; Bernstein JA; Jacobs J; Moldovan D; Riedl MA; Johnston DT; Li HH; Tang Y
Journal
The Journal of Allergy and Clinical Immunology In Practice, Vol. 7, No. 5, pp. 1610–1618.e4
Publisher
Elsevier
Publication Date
May 2019
DOI
10.1016/j.jaip.2019.01.021
ISSN
2213-2198